Hematopoietic Stem Cell Transplantation
Introduction to Hematopoietic Stem Cell Transplantation
- Autologous stem cell transplantation (ASCT) is effective for transplant-eligible patients with multiple myeloma, with improved progression-free survival, according to the Mayo Clinic Proceedings 1
- ASCT is effective for relapsed/refractory lymphoma, particularly in chemosensitive relapse, and should be considered for consolidation in second or third remission, as recommended by the National Comprehensive Cancer Network 2
Indications for Hematopoietic Stem Cell Transplantation
- Allogeneic HSCT is the only potentially curative treatment for myelodysplastic syndrome (MDS), and is recommended for higher-risk MDS patients under 70 years without major comorbidities, with long-term survival rates of 25-45% reported 3, 4
- HLA-matched sibling donor (MSD) HSCT is effective for patients with sickle cell disease (SCD) at risk of neurologic injury or with recurrent vaso-occlusive crises, with best outcomes when performed at the earliest age possible 5
- Stem cell transplantation (SCT) should be discussed in selected cases of Waldenström's macroglobulinemia, with ASCT being feasible and effective for high-risk patients eligible for transplant, most beneficial when offered at early relapses 6
Patient Selection and Evaluation
- Patient selection should be based on disease risk stratification using the Revised International Prognostic Scoring System (IPSS-R), considering patient age, comorbidities, and donor availability 7, 4, 3
- Higher-risk MDS patients should be referred for transplant evaluation at diagnosis, with consideration of proceeding to transplant as soon as a donor is identified 4, 3
- Lower-risk MDS patients should follow surveillance with transplantation only upon disease progression 3
Pre-Transplant Therapy
- Hypomethylating agents (azacitidine or decitabine) are recommended as a bridge to transplantation, especially for patients with ≥10% bone marrow blasts, with at least six cycles recommended 8, 4, 3
- Cytoreductive therapy is recommended prior to transplant if bone marrow blasts ≥10%, with options including hypomethylating agents (HMAs) and intensive chemotherapy 7, 3
- Intensive chemotherapy (ICT) can be considered for younger patients with highly proliferative disease without adverse cytogenetics or TP53 mutations, with complete remission rates around 50% 3
Donor Selection
- The National Comprehensive Cancer Network recommends standard donors in the following order of preference: HLA-identical siblings, syngeneic donors, and 8/8 or 10/10 matched unrelated donors (MUDs) 7
- Alternative donors should be considered for higher-risk patients when no matched donor is available within a reasonable timeframe 7, 3
- Donor characteristics, including age, sex, and cytomegalovirus (CMV) status, should be considered during selection 7, 3
Pre-Transplant Management
- Iron overload should be addressed before transplant, with iron chelation recommended for patients with significant transfusion burden 4
- Collecting stem cells before exposure to certain agents, such as fludarabine, is recommended 6
Post-Transplant Management
- Graft-versus-host disease (GVHD) requires careful management, although specific recommendations are not provided 7
- Disease relapse remains a major challenge, with a probability ranging from 10-40%, particularly in higher-risk disease 7, 3
- Pre-transplant therapy response, especially in patients with TP53 mutations, predicts poor outcomes 3
Prognostic Factors
| Factor | Association with Outcome |
|---|---|
| Performance status (Karnofsky status ≥80%) | Better survival [7] |
| Comorbidity index | Lower index correlates with better outcomes [7] |
| Bone marrow blast percentage | <10% at time of transplantation improves outcomes [7] |
| Cytogenetics | Very poor-risk and monosomal karyotypes have inferior outcomes [7] |
| Molecular mutations | TP53, EZH2, and ETV6 are associated with poor prognosis [7] |